Page last updated: 2024-10-15

8-amino-9-(2-thienylmethyl)guanine

Cross-References

ID SourceID
PubMed CID135400908
CHEMBL ID285627
SCHEMBL ID9665264
MeSH IDM0153509

Synonyms (14)

Synonym
CHEMBL285627 ,
pd-119229-2
pd 119229
bdbm50005795
8-amino-9-(2-thienylmethyl)guanine
104162-90-5
6h-purin-6-one, 2,8-diamino-1,9-dihydro-9-(2-thienylmethyl)-
pd-119,229
SCHEMBL9665264
HANOSGYMKMNFON-UHFFFAOYSA-N
8-amino-9-[(2-thienyl)methyl]guanine
DTXSID50146326
2,8-diamino-9-(thiophen-2-ylmethyl)-1h-purin-6(9h)-one
2,8-diamino-9-(thiophen-2-ylmethyl)-1h-purin-6-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Purine nucleoside phosphorylaseHomo sapiens (human)Ki0.06700.00000.52897.0000AID1571174; AID164920
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
urate biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of T cell proliferationPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationPurine nucleoside phosphorylaseHomo sapiens (human)
allantoin metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nucleobase-containing compound metabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
inosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyinosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
deoxyadenosine catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
purine ribonucleoside salvagePurine nucleoside phosphorylaseHomo sapiens (human)
IMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
nicotinamide riboside catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
immune responsePurine nucleoside phosphorylaseHomo sapiens (human)
nucleotide biosynthetic processPurine nucleoside phosphorylaseHomo sapiens (human)
response to xenobiotic stimulusPurine nucleoside phosphorylaseHomo sapiens (human)
positive regulation of interleukin-2 productionPurine nucleoside phosphorylaseHomo sapiens (human)
purine-containing compound salvagePurine nucleoside phosphorylaseHomo sapiens (human)
dAMP catabolic processPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
nucleoside bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine nucleobase bindingPurine nucleoside phosphorylaseHomo sapiens (human)
purine-nucleoside phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
phosphate ion bindingPurine nucleoside phosphorylaseHomo sapiens (human)
identical protein bindingPurine nucleoside phosphorylaseHomo sapiens (human)
guanosine phosphorylase activityPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
cytosolPurine nucleoside phosphorylaseHomo sapiens (human)
secretory granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
extracellular exosomePurine nucleoside phosphorylaseHomo sapiens (human)
ficolin-1-rich granule lumenPurine nucleoside phosphorylaseHomo sapiens (human)
cytoplasmPurine nucleoside phosphorylaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID223849Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 6 hours at 0.4 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID223847Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 24 hours at 0.4 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID164920Ability to inhibit purine nucleoside phosphorylase (PNP)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID229272Ratio of IC50 ino and Ki ino against purine nucleoside phosphorylase (PNP)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID105110Cytotoxic effect on the growth of human T-and B-lymphoblastoid cell lines(MOLT-4 and MGL-8) evaluated by measuring inhibition of thymidine intake in presence of 10 uM deoxyguanosine1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Inhibitors of human purine nucleoside phosphorylase. Synthesis and biological activities of 8-amino-3-benzylhypoxanthine and related analogues.
AID229634Selectivity ratio is evaluated as (IC50(50 mM PO4) / IC50(1 mM PO4)1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID223848Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 3 hours at 0.4 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID223845Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 0 hours at 0.4 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID223846Compound was evaluated for the inhibitory activity against purine nucleoside phosphorylase (PNP) as a function of time of dialysis after 1 hours at 0.4 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-th
AID156068Inhibition of Purine nucleoside phosphorylase was evaluated against the enzyme from calf spleen in 50 mM phosphate1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID164913Inhibitory activity against Purine nucleoside phosphorylase evaluated by radiochemical assay1992Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8
Inhibitors of human purine nucleoside phosphorylase. Synthesis and biological activities of 8-amino-3-benzylhypoxanthine and related analogues.
AID164764Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using inosine as substrate at a concentration of 10 uM.1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID229806Ratio of Ki ino and Kimesg against purine nucleoside phosphorylase (PNP)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID156067Inhibition of purine nucleoside phosphorylase against the enzyme from calf spleen in 1 mM phosphate1993Journal of medicinal chemistry, Jan-08, Volume: 36, Issue:1
Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-deazaguanine.
AID1571174Inhibition of human PNP2018MedChemComm, Dec-01, Volume: 9, Issue:12
The transition to magic bullets - transition state analogue drug design.
AID164763Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using 2-amino-6-mercapto-7-methyl purine ribonucleoside (MESG) as substrate.1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
AID164756Inhibitory activity against calf spleen purine nucleoside phosphorylase (PNP) using inosine as substrate at a concentration of 10 uM.1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's4 (57.14)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]